San­thera ax­es half its em­ploy­ees and sees CMO de­part af­ter PhI­II DMD fail

Less than a month af­ter show­ing its lead Duchenne mus­cu­lar dy­s­tro­phy pro­gram out the door, San­thera Phar­ma­ceu­ti­cals is slash­ing half its staff.

The Swiss biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER